739 results on '"Sotomayor, Eduardo M."'
Search Results
102. Abstract 257: Class I HDAC inhibition upregulates PD-1 ligands in melanoma and increases the efficacy of PD-1 blockade
103. Abstract 1338: Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy
104. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified
105. Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop
106. Seven Year Followup for Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL)
107. A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma
108. Multivariate Survival Analysis of Transformed Lymphoma in the Chemoimmunotherapy Era: Impact of the NCCN International Prognostic Index
109. The Prognostic Value of the Neutrophil to Lymphocyte Ratio in 209 Patients with Peripheral T-Cell Lymphoma
110. Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)
111. Selective Inhibition of HDAC6 Decreases Viability of Cutaneous T-Cell Lymphoma and Improves Immune Recognition
112. Lymphopenia Is an Adverse Prognostic Factor in EBV-Positive Diffuse Large B-Cell Lymphoma
113. Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL)
114. Histone Deacetylase 11 (HDAC11) As a Novel Transcriptional Regulator of C/EBP-β, in Immature Myeloid Cell to Myeloid Derived Suppressor Cell Transition
115. Increased Treatment Intensity Is Not Associated with a Survival Benefit in Patients with Low and Intermediate Risk Mantle Cell Lymphoma, a Retrospective Analysis
116. Clinical characteristics and prognostic factors of bone lymphomas: focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas
117. Signaling Pathways in Antigen-Presenting Cells Involved in the Induction of Antigen-Specific T-Cell Tolerance
118. Diagnostic Immunophenotype of Acute Promyelocytic Leukemia Before and Early During Therapy With All-trans Retinoic Acid
119. Abstract 4089: Histone deacetylase 6 (HDAC6) as a regulator of PD-L1 expression through STAT3 modulation in melanoma
120. Abstract 643: The histone deacetylase inhibitor Quisinostat augments the anti-tumor reponses of T-cells: Implications in adoptive cell therapy
121. Abstract 2564: Histone deacetylase 6 is a novel target for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination
122. Abstract 4086: Histone deacetylase 6 (HDAC6) as a new target modulating the proliferation and immune-related pathways in melanoma
123. A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs
124. Analysis of prognostic factors in patients with HIV-associated aggressive B-cell non-Hodgkin lymphomas.
125. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis
126. Role Of Histone Deacetylase 6 (HDAC6) In The Modulation Of STAT Pathways and Immune Function Of APCs
127. Histone Deacetylase 6 (HDAC6) Influences T-Cell Activation and Survival: Implications For Cancer Immunotherapy
128. A New Prognostic Index In Diffuse Large B-Cell Lymphoma Using Serum Albumin: A Pilot Study Evaluating The Albumin Adjusted-International Prognostic Index (A-IPI)
129. The Revised International Prognostic Index (R-IPI) Score Is Predictive Of Survival In Aggressive Transformed Lymphomas (TL) From Low Grade Non-Hodgkin Lymphomas In The Chemoimmunotherapy Era
130. Histone Deacetylase 11 (HDAC11) Is a Novel Regulator In The Expansion Of MDSCs Via The Transcription Factor C/EBP-β
131. A Novel Role For Histone Deacetylase 11 (HDAC11) In Plasma Cell Differentation and Survival
132. A Novel Role For Histone Deacetylase 11 (HDAC11) As a Regulator Of Neutrophil Function and Differentiation In Normal and Malignant Hematopoesis
133. Expression Level Of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry Might Correlate With Adverse Clinic Outcome In Adult B- Lymphoblastic Leukemia (B-ALL)
134. What Is The Optimal Dose Of Methotrexate In Primary Central Nervous System Lymphoma Treatment Regimens?
135. Locally Directed Therapy In Limited Stage Mantle Cell Lymphoma
136. Prognostic Significance Of Soft Tissue Involvement and International Prognostic Index In Primary Bone Lymphoma– A Single Institutional Experience
137. A Retrospective Evaluation Of Insurance Status As It Relates To Outcomes In Diffuse Large B-Cell Lymphoma
138. Concurrent Epstein Barr Virus Viremia and Hodgkin Lymphoma In Two Patients With Chronic Lymphocytic Leukemia
139. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity
140. Quantitative Flow Cytometric Analysis in Erythrodermic Cutaneous T-Cell Lymphoma: Implications for Prognosis and Staging
141. Abstract 4944: Combined treatment of BTK and PI3K inhibitors synergistically disrupts BCR-signaling, overcomes microenviroment-mediated survival and drug resistance in mantle cell lymphoma.
142. Abstract 5246: Histone deacetylase 6 (HDAC6) as a new modulator of the JAK/STAT pathway in melanoma.
143. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified.
144. Histone Deacetylase 11 (HDAC11) Regulates Cytotoxic T-Cell Function and Memory Phenotype
145. Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)
146. Critical Role for Histone Deacetylase 6 (HDAC6) in the Regulation of IL-6, and the JAK/STA3 Signaling Cascade in Macrophages
147. Cytarabine Either with Induction or Conditioning May Improve Outcomes Among Those Undergoing Autologous Transplantation in First or Second Remission for Mantle Cell Lymphoma
148. Physical Interaction of Histone Deacetylase 6 (HDAC6) with STAT3 Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs)
149. BTK inhibitor PCI-32765 targets endogenous and microenvironment-mediated B-cell receptor signaling to suppress lymphoma cell growth and is highly synergistic with Bortezmib against non-Hodgkin B-cell lymphomas
150. Autologous Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.